NRx Pharma Stock Is Trading Higher On Positive Aviptadil Data From Expanded Access Protocol In COVID-19 Patients

NRx Pharmaceuticals Inc NRXP has announced positive data from its Zyesami (Aviptadil) Expanded Access Protocol (EAP) in patients with critical COVID-19 and respiratory failure.
Overall, patients receiving at least one dose of Zyesami in addition to intensive care were alive at 28 days.
This EAP includes sick patients for whom no other options were available and could not enroll in a study due to additional risk factors.
Among patients receiving maximal intensive (i.e., non-palliative) care, 76% of those treated with high nasal flow cannula (HFNC) were discharged from the hospital or were alive and in the hospital at day 28, compared to 54% of those treated with mechanical ventilation.
Treatment-related adverse events from this EAP are congruent with those seen in the randomized controlled phase 2b/3 clinical trial of Zyesami. Treatment-related adverse events included diarrhea (5%) and hypotension (5%). Other adverse events included tachycardia and flushing.
The EAP data are being provided to FDA as "real-world data" in support of the findings from the Zyesami randomized controlled phase 2b/3 clinical trial.
Price Action: NRXP shares are up 12.5% at $20.25 during the premarket session on the last check Tuesday.